SCHEMBL136187

SCHEMBL136187

CCOC(=O)c1cnnn1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CYP1A2 P05177 3/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
CYP3A4 P08684 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB2 P47870 2/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
LMNA P02545 2/20 0.40
ABCB11 O95342 1/20 0.40
GABRA2 P47869 1/20 0.40
TSHR P16473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2518495 0.82 LMNA (0.46) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL31094801 0.81 PTGS2 (0.43) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL9920418 0.81 CYP2C9 (0.42) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL1430801 0.78 CYP1A2 (0.44) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL29224177 0.74 PTGS2 (0.39) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL16815462 0.74 GAA (0.41) CYP2C9CYP2C19CYP3A4LMNATSHR
SCHEMBL30322813 0.74 PTGS2 (0.39) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL29224211 0.74 PTGS2 (0.39) CYP2C9CYP2C19CYP1A2CYP3A4GABRA1
SCHEMBL8156087 0.74 TP53 (0.58) GABRB2LMNAGABRA2SMN1; SMN2MEN1
SCHEMBL29224302 0.74 PTGS2 (0.41) CYP2C9CYP2C19CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252511-B2 Process for the preparation of cyclic depsipeptides ONKURE, INC. (US) 2025-03-18 US claimed
US-20250074882-A1 IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2025-03-06 US claimed
CN-117843715-A Liquid phase synthesis method of melanoputan-II 浙江工业大学 2024-04-09 CN claimed
CN-117843761-A Method for preparing melanocortin analogue cyclic peptide drug based on hydrophobic label carrier 浙江工业大学 2024-04-09 CN claimed
CN-117736262-A Preparation method of tripeptide-1 深圳创元生物医药科技有限公司 2024-03-22 CN claimed
EP-4201951-B1 METHOD FOR PEPTIDE SYNTHESIS BACHEM HOLDING AG (CH) 2023-11-22 EP claimed
WO-2023117904-A1 METHOD FOR PEPTIDE SYNTHESIS BACHEM HOLDING AG (CH) 2023-06-29 WO claimed
EP-4201951-A1 METHOD FOR PEPTIDE SYNTHESIS Bachem Holding AG (CH) 2023-06-28 EP claimed
CN-115093460-A Method for synthesizing linaclotide intermediate and linaclotide in full liquid phase 浙江工业大学 2022-09-23 CN claimed
US-9353147-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 US claimed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 US claimed
US-12637431-B2 Process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2026-05-26 US disclosed
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2026-05-21 US disclosed
CN-121889409-A Method for producing peptide compounds using independent condensing agents 中外制药株式会社 2026-04-17 CN disclosed
EP-3916000-B1 METHOD FOR PRODUCING PEPTIDE COMPOUND, PROTECTING GROUP-FORMING REAGENT, AND AROMATIC HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2026-04-08 EP disclosed
US-8546534-B2 Branched chain-containing aromatic compound AJINOMOTO CO., INC. (JP) 2013-10-01 US disclosed
EP-2612845-A1 AROMATIC COMPOUND CONTAINING SPECIFIC BRANCH Ajinomoto Co., Inc. (JP) 2013-07-10 EP disclosed
EP-2518041-A1 BENZYL COMPOUND Ajinomoto Co., Inc. (JP) 2012-10-31 EP disclosed
US-20120059149-A1 BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND AJINOMOTO CO. INC. (JP) 2012-03-08 US disclosed
US-20110160433-A1 BENZYLIC COMPOUND AJINOMOTO CO., INC. (JP) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160433-A1 BENZYLIC COMPOUND VIP, NGLY1, FURIN CYP2C9 1641/4885CYP2C19 1494/4885CA12 368/4885
US-20120059149-A1 BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND VIP, BCAT2, IAPP CYP2C9 2936/4885CYP2C19 3470/4885CA12 2862/4885
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE ANPEP, NPPA, LNPEP CYP2C9 4796/4885CYP2C19 4855/4885CA12 414/4885
US-20250074882-A1 IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE ABL1, JAK1, FGFR1 CYP2C9 96/4885CYP2C19 101/4885CA12 4410/4885
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF STXBP1, HBB, UPF1 CYP2C9 4711/4885CYP2C19 4877/4885CA12 4676/4885
US-12637431-B2 Process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof OPRD1, OPRK1, OPRM1 CYP2C9 41/4885CYP2C19 99/4885CA12 4051/4885
US-12252511-B2 Process for the preparation of cyclic depsipeptides VIP, LPXN, NGLY1 CYP2C9 1698/4885CYP2C19 1630/4885CA12 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.